{
    "id": 20867,
    "cites": 57,
    "cited_by": 25,
    "reference": [
        "Akscin, John, Thomas R. Barr, and Elaine L. Towle. 2007. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Key Practice Indicators in OfficeBased Oncology Practices: 2007 Report on 2006 Data.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Clinical Oncology 3(4): 2003.",
        "Anand, Geeta. 2007. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Prescribing Caution: From Wall Street, a Warning About Cancer-Drug Prices; Morgan Stanley Analyst Creates Stir in Industry As He Sees a Backlash.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Wall Street Journal, March 15. http://online.wsj.com/news/articles/SB117391934158537592 Bach, Peter B. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine 360(6): 626-33.",
        "Bach, Peter B., Leonard B. Saltz, and Robert E. Wittes. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093In Cancer Care, Cost Matters.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The New York Times, October 14. http://www.nytimes.com/2012/10/15/ Conti, Rena M., Peter B. Bach. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Cost Consequences of the 340B Drug Discount Program.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the American Medical Association 309(19): 1995-6.",
        "Berndt, Ernst R., David Cutler, Richard G. Frank, Zvi Griliches, Joseph P. Newhouse, and Jack E. Triplett, 2000. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medical Care Prices and Output,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Chap. 3, In Handbook of Health Economics, Vol. 1A. edited by J.P. Newhouse and A.C. Culyer. Amsterdam: Elsevier Science B.V. Berndt, Ernst R., and Joseph P. Newhouse. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pricing and Reimbursement in US Pharmaceutical Markets.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Chap. 8 in The Oxford Handbook of the Economics of the Biopharmaceutical Industry, edited by P.M. Danzon and S.N. Nicholson. New York, NY: Oxford University Press.",
        "Biotechnology Industry Organization. 2013. The 340B Drug Discount Program.",
        "http://www.bio.org/sites/default/files/340B percent20White percent20Paper percent20FINAL.pdf Budish, Eric, Benjamin N. Roin, Heidi Williams. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do Fixed Patent Terms Distort Innovation? Evidence from Cancer Clinical Trials.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research working paper 19430.",
        "Busch, Susan H., Ernst R. Berndt, and Richard G. Frank. 2001. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Creating Price Indexes for Measuring Productivity in Mental Health Care.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Chap. 5 in Frontiers in Health Policy Research, Vol. 4, edited by A.M. Garber. Cambridge, MA: MIT Press for the National Bureau of Economic Research.",
        "Cavalli, Franco. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An Appeal to World Leaders: Stop Cancer Now.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Lancet 381(9865): 425-6.",
        "Caves, Richard E., Michael D. Whinston, and Mark A. Hurwitz. 1991. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent Expiration, Entry and Competition in the US Pharmaceutical Industry: An Exploratory Analysis.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Brookings Papers on Economic Activity. Microeconomics 1-48.",
        "Center for Medicare & Medicaid Services. 2014. CMS proposes program changes for Medicare Advantage and Prescription Drug Benefit Programs for Contract Year 2015 (CMS-4159-P).",
        "January 6. http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-Sheets/2014-Factsheets -items/2014-01-06.html CenterWatch. 2014. FDA Approved Drugs for Oncology. http://www.centerwatch.com/druginformation /fda-approved-drugs/therapeutic-area/12/ Chen, Jie, and John A. Rizzo. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pricing Dynamics and Product Quality: The Case of Antidepressant Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Empirical Economics 42(1): 279-300.",
        "Conti, Rena M., Arielle C. Bernstein, Victoria M. Villaflor, Richard L. Schilsky, Meredith B. Rosenthal, and Peter B. Bach. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Clinical Oncology 31(9): 1134-9.",
        "Conti, Rena M., and Peter B. Bach. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Cost Consequences of the 340B Drug Discount Program.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the American Medical Association 309(19): 1995-6.",
        "Cockburn, Iain M., and Aslam H. Anis. 2001. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Hedonic Analysis of Arthritis Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Chap. 11 in Medical Care Output and Productivity, edited by E. Berndt and D. Cutler. Chicago, IL: University of Chicago Press.",
        "Dendreon. 2014. Patient Access. http://www.dendreon.com/patient_resources/patient_access/ Drug Discount Monitor. 2014. 340B Sales Totaled $7.5 Billion in 2013, Apexus Says. February 14. http://drugdiscountmonitor.com/2014/02/340b-sales-totaled-7-5-billion-in-2013-apexus-says/ Experts in Chronic Myeloid Leukemia. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Price of Drugs for Chronic Myeloid Leukemia (CML) is a Reflection of the Unsustainable Prices of Cancer Drugs: From the Perspective of a Large Group of CML Experts.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Blood 121(22): 4439-42.",
        "Fleck, Leonard. 2013. Just Caring: Can We Afford the Ethical and Economic Costs of Circumventing Cancer Drug Resistance?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Personalized Medicine 3(3): 124-43.",
        "Frank, Richard G., and David S. Salkever. 1997. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Entry and the Pricing of Pharmaceuticals.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economics and Management Strategy 6(1): 75-90.",
        "Frey, Bruno S., and Werner W. Pommerehne. 1993. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093On the Fairness of Pricing--An Empirical Survey among the General Population.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Behavior and Organization 20(3): 295-307.",
        "Gingrich, Newt. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Trust the Government.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Human Events. August 12. http://humanevents.com/2009/08/12/trust-the-government/ Goldman, Dana P., Anupam B. Jena, Darius N. Lakdawalla, Jennifer L. Malin, Jesse D. Malkin, and Eric Sun. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Value of Specialty Oncology Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Service Research 45(1): 115-32.",
        "Griffith, Victoria. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pricing Weighs on Cancer Treatments.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Financial Times, June 03.",
        "http://www.ft.com/intl/cms/s/0/8a7697f6-b4fa-11d8-81c6-000e2511c801.html#axzz38sOrHssv Hall, Stephen S. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Cost of Living.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New York Magazine. October 20. http://nymag.com/news/features/cancer-drugs-2013-10/ Hirth, Richard A, Michael E. Chernew, Edward Miller, A. Mark Fendrick and William G.",
        "Weissert. 2000. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Willingness to Pay for a Quality-Adjusted Life Year: In Search of a Standard.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Medical Decision Making 20(3): 332-42.",
        "Howard, David H. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Companies\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Patient-Assistance Programs \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c Helping Patients or Profits?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine. 371(2): 97-9.",
        "Hutchison, Courtney. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Provenge Cancer Vaccine: Can You Put a Price on Delaying Death?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d ABC News. July 29. http://abcnews.go.com/Health/ProstateCancerNews/provengecancer -vaccine-months-life-worth-100k/story?id=11269159 IMS Institute for Healthcare Informatics. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Innovation in Cancer Care and Implications for Health Systems: Global Oncology Trend Report\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Available at: http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22 a/?vgnextoid=f8d4df7a5e8b5410VgnVCM10000076192ca2RCRD.",
        "InsideHealthPolicy. 2014. MedPAC Explores Fixes To Part B Drug Payment Policy, Calls Current System \u00c3\u00a2\u00e2\u0082\u00ac\u00cb\u009cPerverse Incentive\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2. http://www.pipcpatients.org/pipcadmin /pdf/cde114_MedPAC%20Explores%20Fixes%20To%20Part%20B%20Drug%20Paymen t%20Policy.pdf Jacobson, Mireille, A. James O\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2Malley, Craig C. Earle, Juliana Pakes, Peter Gaccione, and Joseph P.Newhouse. 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Does Reimbursement Influence Chemotherapy Treatment for Cancer Patients?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 25(2): 437-43.",
        "Jacobson, Mireille, Craig C. Earle, Mary Price, and Joseph P. Newhouse. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 29(7): 1391-9.",
        "Kahneman, Daniel, Jack L. Knetsch, and Richard H. Thaler, 1986. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Fairness as a Constraint on Profit Seeking: Entitlements in the Market.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review 76(4): 728-41.",
        "Kaiser Family Foundation and Health Research & Educational Trust. 2013. Employer Health Benefits. 2013 Annual Survey. Washington, D.C.: Kaiser Family Foundation and Health Research & Educational Trust.",
        "Kalyanaram, Gurumurthy, and John D.C. Little. 1994. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An Empirical Analysis of Latitude of Price Acceptance in Consumer Package Goods.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Consumer Research 21(3): 408-18.",
        "Lakdawalla, Darius N, John A. Romley, Yuri Sanchez, J. Ross Maclean, John R. Penrod, and Tomas Philipson. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How Cancer Patients Value Hope and the Implications for CostEffectiveness Assessments of High-Cost Cancer Therapies.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 31(4): 676-82.",
        "Landsem, Hope. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Rationing Health Care in Oregon.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Wall Street Journal, August 8.",
        "http://online.wsj.com/news/articles/SB10001424127887324522504579000560184822956 Kantarjian, Hagop M, Tito Fojo, Michael Mathisen, and Leonard A. Zwelling. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Cancer Drugs in the United States: Justum Pretium--The Just Price.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Clinical Oncology 31(28): 3600-4.",
        "Lichtenberg, Frank. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Effect of New Cancer Drug Approvals on the Life Expectancy of American Cancer Patients, 1978-2004.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Economics of Innovation and New Technology 18(5): 407-28.",
        "Lichtenberg, Frank R. 2009. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093International Differences in Cancer Survival Rates: The Role of New Drug Launches.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d International Journal of Healthcare Technology and Management 10(3): 138-55.",
        "Lu, Z. John and William S. Comanor. 1998. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Strategic Pricing of New Pharmaceuticals. Review of Economics and Statistics 80(1): 108-18.",
        "Lucarelli, Claudio, and Sean Nicholson, 2009, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Quality-Adjusted Price Index for Colorectal Cancer Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research working paper 15174.",
        "Marcus, Amy D. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Price Becomes Factor in Cancer Treatment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Wall Street Journal September 7. http://online.wsj.com/news/articles/SB109450779986210547 Mas, Alexandre. 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pay, Reference Points, and Police Performance.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 121(3): 783-821.",
        "Maxwell, Sarah. 2002. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Rule-Based Price Fairness and Its Effect on Willingness to Purchase.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Psychology 23(2): 191-212.",
        "National Comprehensive Cancer Network. 2010. Guidelines for Breast Cancer Updated; Bevacizumab Recommendation Affirmed. http://www.nccn.org/about/news/newsinfo.asp?NewsID = 259.",
        "National Cancer Institute. 2014. Cancer Drug Information. http://www.cancer.gov/cancertopics/druginfo/alphalist Neumann, Peter J. 2005. Using Cost-Effectiveness Analysis to Improve Health Care. Oxford, United Kingdom; Oxford University Press.",
        "Newhouse, Joseph P. 1992. Medical Care Costs: How Much Welfare Loss? Journal of Economic Perspectives 6(3): 3-21.",
        "Niraula, Saroj, Bostjan Seruga, Alberto Ocana, Tiffany Shao Robyn Goldstein, Ian F. Tannock, and Eitan Amir. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Clinical Oncology 30(24): 3012-9.",
        "PhRMA (Pharmaceutical Research and Manufacturers of America). 2014. Medicines in Development. 2014. http://www.phrma.org/innovation/meds-in-development Piron, Robert, and Luis Fernandez. 1995. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Are Fairness Constraints on Profit-Seeking Important?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Psychology 16(1): 73-96.",
        "Raborn Martin L., Elise M. Pelletier, Daniel B. Smith, and Carolina M. Reyes. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patient Out-of-Pocket Payments for Oral Oncolytics: Results from a 2009 US Claims Data Analysis.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Journal of Managed Care 18(5 No. 2): SP57-64.",
        "Reekie, W. Duncan. 1978. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Price and Quality Competition in the United States Drug Industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Journal of Industrial Economics 26(3): 223-37.",
        "Romley, John A, Yuri Sanchez, John R. Penrod, and Dana P. Goldman. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Survey Results Show That Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 31(4): 683-90.",
        "Schrag, Deborah. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Price Tag on Progress--Chemotherapy for Colorectal Cancer.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine 351(4): 317-9.",
        "Seabury, Seth A., Dana P. Goldman, J. Ross Maclean, John R. Penrod, and Darius N. Lakdawalla. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patients Value Metastatic Cancer Therapy More Highly Than is Typically Shown Through Traditional Estimates.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 31(4): 691-9.",
        "Silber, Judy. 2005. Onyx Gets OK for Kidney Cancer Drug. Contra Costa Times December 21.",
        "Sun, Eric, Anupam B. Jena, Darius Lakdawalla, Carolina Reyes, Tomas J. Philipson, and Dana Goldman. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Contributions of Improved Therapy and Early Detection to Cancer Survival Gains, 1988-2000.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forum for Health Economics & Policy 13(2): 1-20.",
        "Suslow, Valerie Y. 1996. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Measuring Quality Change in Pharmaceutical Markets: Hedonic Price Indexes for Anti-Ulcer Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Chap. 4 in Competitive Strategies in the Pharmaceutical Industry, edited by R. Helms. Washington, D.C.: American Enterprise Institute.",
        "Szabo, Liz. 2004 \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Price of Cancer Drugs Called \u00c3\u00a2\u00e2\u0082\u00ac\u00cb\u009cMind-Boggling\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d USA Today. July 21. http://usatoday30.usatoday.com/news/health/2004-07-21-cancer-usat_x.htm Thaler Richard. 1985, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Mental Accounting and Consumer Choice,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Marketing Science 4(3): 199-214.",
        "Trusheim, Mark R., and Ernst R. Berndt. 2012. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Segmentation of Therapeutic Populations in Oncology.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Management, Policy and Innovation 1(1): 19-34.",
        "US Food and Drug Administration. 2014a. Table of Pharmacogenomic Biomarkers in Drug Labeling. August 18. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm US Food and Drug Administration. 2014. Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review. September 18, 2014.",
        "http://www.fda.gov/ForPatients/Approvals/Fast/default.htm US General Accounting Office. 2011. Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement. Washington, D.C.",
        "Wittes, Robert E. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Cancer Weapons, Out of Reach.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Washington Post June 15. http://www.washingtonpost.com/wp-dyn/articles/A42035-2004Jun14.html Woodward, Rebecca M, Martin L. Brown, Susan T. Stewart, Kathleen A. Cronin, and David M.",
        "Cutler. 2007. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Value of Medical Interventions for Lung Cancer in the Elderly: Results from SEER-CMHSF.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Cancer 110(11): 2511-8. Price on log scale ($1,000s of USD) 0.1 0.2 0.5 1.0 2.0 3.0 5.0 Life years gained on log scale (years) Source of survival benefit: Trial, overall survival Trial, progression-free survival Modelling study Source: Authors"
    ]
}